India embracing AI in clinical trials

31 July 2023

digital_ai_data_artificial_intelligence_big

Change is in the air for the Indian clinical trial market. The rapid approval of COVID-19 vaccinations during the SARS-CoV-2 pandemic illustrated the value of clinical studies that could improve therapeutic regimens, and advance evidence-based medicine.

With the use of artificial intelligence (AI) thrown in the mix, the Indian government and regulatory bodies have taken several steps to promote its adoption, reports The Pharma Letter’s India correspondent.

Looking to establish an ethical framework that can assist in the development, deployment, and adoption of AI-based solutions in the clinical trial arena, the Indian Council for Medical Research (ICMR) recently released its first ethical guidelines for AI application in Biomedical Research and Healthcare.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK